Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Pinyol, Roser; Montal, Robert; Bassaganyas, Laia; Sia, Daniela; Takayama, Tadatoshi; Chau, Gar-Yang; Mazzaferro, Vincenzo; Roayaie, Sasan; Chu Lee, Han; Kokudo, Norihiro; Zhang, Zhongyang; Torrecilla, Sara; Moeini, Agrin; Rodríguez‐Carunchio, Leonardo; Gane, Edward; Verslype, Chris; Croitoru, Adina; Cillo, Umberto; de la Mata, Manuel; Lupo, L.; I. Strasser, Simone; Park, Joong‐Won; Camps, Jordi; Solé, Manel; N. Thung, Swan; Villanueva, Augusto; Peña, Carol; Meinhardt, Gerold; Bruix, Jordi; M. Llovet, Josep

doi:10.1136/gutjnl-2018-316408

Public

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Published in Gut • Aug 14, 2018

Authors:

Roser Pinyol

Robert Montal

Laia Bassaganyas

Abstract

Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve...

Subject

Sorafenib

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!